Impact of PET/CT in comparison with same day contrast enhanced CT in breast cancer management

Clinical Nuclear Medicine

Volumn 32, Issue 6, 2007, Pages 429-434

  Piperkova, Elena ^a   Raphael, Barbara ^a   Altinyay, Mustafa E ^a   Castellon, Ivan ^a   Libes, Richard ^a   Sandella, Nick ^a   Heiba, Sherif ^a   Abdel Dayem, Hussein ^a,b  

^a ST VINCENT S COMPREHENSIVE CANCER CENTER   (United States)

^b ST VINCENT S HOSPITAL   (United States)

Author keywords

Breast cancer staging; Contrast enhanced CT (CE CT); PET CT; Restaging

Indexed keywords

CONTRAST MEDIUM; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; BODY REGIONS; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DRUG UPTAKE; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; HUMAN; IMAGING SYSTEM; INTERMETHOD COMPARISON; LIVER METASTASIS; LIVER NECROSIS; LYMPH NODE METASTASIS; MALE; POSITRON EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY; TUMOR BIOPSY; WHOLE BODY CT; WHOLE BODY SCINTISCANNING;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 34249038610     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/RLU.0b013e31805375e0     Document Type: Article

References (36)

1. Guarneri V, Conte PF. The curability of breast cancer and treatment of advanced disease. Eur J Nucl Med Mol Imaging. 2004;31(Suppl 1): S149-S161.
2. Jemal A, Thomas A, Murray T, et al. Cancer statistics 2002. CA Cancer J Clin. 2002;52:23-47.
3. Sant M, Allemani C, Berrino F, et al. Breast carcinoma survival in Europe and United states. Cancer. 2004;100:715-722.
4. Eubank WB. Diagnosis of recurrent and metastatic Disease using F-18fluorodeoxyglucose-positron emission tomography. PET Clin. 2006;1:15-24.
5. Wahl RL, Siegel BA, Coleman RE, et al. Prospective Multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of staging breast cancer with PET study group. J Clin Oncol. 2004;22:277-285.
6. Eubank WB, Mankoff DA, Takasugi J, et al. 18Fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer. J Clin Oncol. 2001;19:3516-3523.
7. Kostakoglu L, Hardoff R, Mircheva R, et al. PET-CT fusion imaging in differentiating physiologic from pathologic FDG uptake. Radiographics. 2004;24:1411-1431.
8. Eubank WB, Mancoff DA, Schmield UP, et al. Imaging of oncologic patients: benefit of combined CT and fluorodeoxyglucose positron emission tomography scan interpretation in the diagnosis of malignancy. AJR Am J Roentgenol. 1998;171:1103-1110.
9. Kluetz PG, Meltzer CC, Villemenagne VL, et al. Combined PET/CT imaging in oncology: impact on patients management. Clin Positron Imaging. 2000;3:223-230.
10. Cohade C, Osman M, Pannu HK, Wahl RL. Uptake in supraclavicular area fat ("USA-Fat"): description on 18F FDG PET/CT. J Nucl Med. 2003;44:170-176.
11. Schoder H, Yeung HWD, Larson SM. CT in PET/CT: essential Features of interpretation. J Nucl Med. 2005;46:1249-1251.
12. Osman MM, Cohade C, Fishman EK, et al. Clinically Significant incidental findings on the unenhanced CT portion of PET/CT studies: frequency in 250 patients. J Nucl Med. 2005;46:1352-1355.
13. Avril N, Adler LP. F-18 Fluorodeoxyglucose-positron emission tomography imaging for primary breast cancer and loco-regional staging. PET Clin. 2006;1:1-13.
14. Zangheri B, Messa C, Picchio M, et al. PET/CT in breast cancer. Eur J Nucl Med Mol Imaging. 2004;31(Suppl 1):S135-S142.
15. Reinartz P, Wieres F-J, Schneider W, et al. Side by side reading of PET and CT scans in oncology: which patients might profit from integrated PET/CT. Eur J Nucl Med and Mol Imaging. 2004;31:1456-1461.
16. Hollinger EF, Alibazoglu H, Ali A, et al. Hematopoetic cytokine mediated FDG uptake simulates the appearance of diffuse metastatic disease on whole-body PET imaging. Clin Nucl Med. 1997;23:93-98.
17. Abdel-Dayem HM, Rosen G, El-Zaftaway H, et al. Fluorine-18 fluorodexyglucose splenic uptake from extramedulary hematopoiesis after granulocyte colony stimulating factor stimulation. Clin Nucl Med. 1999;24:319-322.
18. Kazama T, Swanston N, Podoloff D, et al. Effect of colony-stimulating factor and conventional- or high-dose chemotherapy on FDG uptake in bone marrow. Eur J Nucl Med and Mol Imaging. 2005;32:1406-1410.
19. Ganatra RD. Doctor's dilemma (medical decision making). World J Nucl Med. 2003;2:70-75.
20. Bender H, Kirst J, Palmedo H, et al. Value of 18fluorodeoxyglucose positron emission tomography in the staging of recurrent breast carcinoma. Anticancer Res. 1997;17:1687-1692.
21. Moon DH, Maddahi J, Silverman DHS, et al. Accuracy of whole-body [fluorine-18]-FDG-PET for detection of recurrent or metastatic breast carcinoma. J Nucl Med. 1998;39:431-435.
22. Avril N, Schelling M, Dose J, et al. Utility of PET in breast cancer. Clin Positron imaging. 1999;2:261-271.
23. Lonneux M, Borbath I, Berliere M, et al. The place of whole-body FDG-PET for the diagnosis of distant recurrence of breast cancer. Clin Positron Imaging. 2000;3:45-49.
24. Liu CS, Shen YY, Lin CC, et al. Clinical impact of [18F] FDG-PET in patients with suspected recurrent breast cancer, based of asymptomatically elevated tumor marker serum levels: a preliminary report. Jpn J Clin oncol. 2002;32:244-247.
25. Gallowitsch HJ, Kresnik E, Gasser J, et al. [18F]-Fluorodeoxyglucose positron emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison with conventional imaging. Invest Radiol. 2003;38:250-256.
26. Siggelkow W, Zimny M, Faridi A, et al. The value of positron emission tomography in the follow-up of breast cancer. Anticancer Res. 2003;23:1859-1868.
27. Kamel EM, Wyss MT, Fehr MK, et al. [18F] Fluorodeoxyglucose positron emission tomography in patients with suspected recurrence of breast cancer. J Cancer Res Clin Oncol. 2003;129:147-153.
28. Eubank WB, Mancoff DA, Vessell HJ, et al. Detection of loco-regional and local recurrences in breast cancer patients by using FDG-PET. Radiographics. 2002;22:5-17.
29. Kumar R, Loving VA, Chauhan A, et al. Potential of dual-time-point imaging to improve breast cancer diagnosis with 18FDG PET. J Nucl Med. 2005;46:1819-1824.
30. Yap CS, Seltzer MA, Scipers C, et al. Impact of whole-body 18FDG-PET on staging and managing patients with breast cancer: the referring physician's perspective. J Nucl Med. 2001;42:1334-1337.
31. Eubank WB, Mankoff DA, Bhattacharya M, et al. Impact of [18F-18]-Fluorodeoxiglucose PET on difiniting the extent of disease and management of patients with recurrent or metastatic breast cancer. Am J Roentgenol. 2004;83:479-486.
32. Jacene HA, Stearns V, Wahl RL. Lymphadenopathy resulting from acute hepatitis C infection mimicking metastatic breast carcinoma on FDG PET/CT. Clin Nucl Med. 2006;31:379-381.
33. Boerner AR, Weckesser M, Herzog H, et al. Optimal scan time for fluorine-18 fluorodeoxy glucose positron emission tomography in breast cancer. Eur J Nucl Med. 1999;26:226-230.
34. Zhang H, Pourdehnad M, Lambright ES, et al. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. Eur J Nucl Med Mol Imaging. 2002;29:1317-1323.
35. Pelosi E, Messa C, Sironi S, et al. Value of integrated PET/CT for lesion localization in cancer patients: a comparative study. Eur J Nucl Med Mol Imaging. 2004;31:932-939.
36. Tatsumi M, Cohade C, Mourtzikos KA, et al. Initial experience with FDG-PET/CT in the evaluation of breast cancer. Eur J Nucl Med Mol Imaging. 2006;33:254-262.